pirenzepine has been researched along with Obesity in 29 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "A pilot study was conducted to evaluate the effect of nizatidine on olanzapine-associated weight gain (OAWG) in ten patients with schizophrenia and schizophreniform disorder in Korea." | 9.10 | Effect of nizatidine on olanzapine-associated weight gain in schizophrenic patients in Korea: a pilot study. ( Bahk, WM; Kim, JJ; Lee, C; Lee, CU; Lee, KU; Lee, SJ; Pae, CU; Paik, IH, 2003) |
| "It has been reported that nizatidine may reduce the weight gain in schizophrenic patients receiving olanzapine treatment." | 9.10 | Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain. ( Atmaca, M; Kuloglu, M; Tezcan, E; Ustundag, B, 2003) |
| "The authors studied weight gain mechanisms and energy balance in patients treated with olanzapine." | 9.10 | Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. ( Apter, A; Constantini, N; Falk, B; Frishman, S; Gothelf, D; Kairi, M; Phillip, M; Poraz, I; Singer, P; Weizman, A; Zalsman, G; Zigel, L, 2002) |
| "First-episode hospitalized schizophrenia patients (N=30) were randomly assigned in an 8-week double-blind study of olanzapine, 10 mg/day, coadministered with either fluoxetine, 20 mg/day (N=15), or placebo (N=15)." | 9.10 | Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. ( Fuchs, C; Gil-Ad, I; Maayan, R; Pashinian, A; Poyurovsky, M; Schneidman, M; Weizman, A, 2002) |
| "Acute cholinergic muscarinic blockade with pirenzepine significantly reduces meal stimulated plasma insulin and plasma glucose concentrations in clinically hyperandrogenic women with polycystic ovary syndrome." | 9.07 | Acute cholinergic blockade with low dose pirenzepine reduces the insulin and glucose responses to a mixed meal in obese women with the polycystic ovary syndrome. ( Ismail, IS; Miell, JP; Peters, JR; Premawardhana, LD; Riad-Fahmy, D; Scanlon, MF, 1994) |
| "A patient with olanzapine temporally associated weight gain was treated with nizatidine as "add-on" therapy." | 7.70 | H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients. ( Bravi, D; Guarneri, L; Sacchetti, E, 2000) |
| "A pilot study was conducted to evaluate the effect of nizatidine on olanzapine-associated weight gain (OAWG) in ten patients with schizophrenia and schizophreniform disorder in Korea." | 5.10 | Effect of nizatidine on olanzapine-associated weight gain in schizophrenic patients in Korea: a pilot study. ( Bahk, WM; Kim, JJ; Lee, C; Lee, CU; Lee, KU; Lee, SJ; Pae, CU; Paik, IH, 2003) |
| "It has been reported that nizatidine may reduce the weight gain in schizophrenic patients receiving olanzapine treatment." | 5.10 | Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain. ( Atmaca, M; Kuloglu, M; Tezcan, E; Ustundag, B, 2003) |
| "The authors studied weight gain mechanisms and energy balance in patients treated with olanzapine." | 5.10 | Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. ( Apter, A; Constantini, N; Falk, B; Frishman, S; Gothelf, D; Kairi, M; Phillip, M; Poraz, I; Singer, P; Weizman, A; Zalsman, G; Zigel, L, 2002) |
| "First-episode hospitalized schizophrenia patients (N=30) were randomly assigned in an 8-week double-blind study of olanzapine, 10 mg/day, coadministered with either fluoxetine, 20 mg/day (N=15), or placebo (N=15)." | 5.10 | Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. ( Fuchs, C; Gil-Ad, I; Maayan, R; Pashinian, A; Poyurovsky, M; Schneidman, M; Weizman, A, 2002) |
| "We performed a retrospective analysis of 122 clinical records of 92 male patients with DSM-III-R schizophrenia to examine the relative weight gain liabilities of clozapine, risperidone, olanzapine, and sertindole compared with haloperidol." | 5.09 | Novel antipsychotics: comparison of weight gain liabilities. ( Berisford, MA; Goldstein, D; Kysar, L; Marder, SR; Mintz, J; Pashdag, J; Wirshing, DA; Wirshing, WC, 1999) |
| "Acute cholinergic muscarinic blockade with pirenzepine significantly reduces meal stimulated plasma insulin and plasma glucose concentrations in clinically hyperandrogenic women with polycystic ovary syndrome." | 5.07 | Acute cholinergic blockade with low dose pirenzepine reduces the insulin and glucose responses to a mixed meal in obese women with the polycystic ovary syndrome. ( Ismail, IS; Miell, JP; Peters, JR; Premawardhana, LD; Riad-Fahmy, D; Scanlon, MF, 1994) |
| "The study population comprised 56 patients with DSM-IV schizophrenia, who were divided into 4 treatment groups: quetiapine (N = 14), olanzapine (N = 14), risperidone (N = 14), or clozapine (N = 14) monotherapy, and a control group of 11 patients receiving no psychopharmacologic treatment." | 3.72 | Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. ( Atmaca, M; Kuloglu, M; Tezcan, E; Ustundag, B, 2003) |
| "One of my patients is taking olanzapine for schizophrenia." | 3.71 | Maternal obesity and risk of neural tube defects. ( Koren, G, 2001) |
| "A patient with olanzapine temporally associated weight gain was treated with nizatidine as "add-on" therapy." | 3.70 | H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients. ( Bravi, D; Guarneri, L; Sacchetti, E, 2000) |
| "Peak plasma glucose in NIDDMs was reduced following pirenzepine (12." | 2.67 | Cholinergic blockade with pirenzepine induces dose-related reduction in glucose and insulin responses to a mixed meal in normal subjects and non-insulin dependent diabetics. ( Ara, J; Bevan, JS; Page, MD; Peters, JR; Scanlon, MF, 1991) |
| "Psychopharmacology research aims to expand the therapeutic ratio between efficacy, on the one hand, and adverse events and safety, on the other." | 1.31 | Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited. ( McIntyre, RS, 2002) |
| "Weight gain has been reported with nearly every antipsychotic drug on the market (molindone is an exception)." | 1.30 | Weight gain associated with antipsychotic drugs. ( Ganguli, R, 1999) |
| " We have evaluated the consequences of HFD on heart rate (HR) and blood pressure (BP) circadian cycles and methylscopolamine dose-response curves." | 1.30 | Impaired atrial M(2)-cholinoceptor function in obesity-related hypertension. ( Berlan, M; Galitzky, J; Merial, C; Montastruc, JL; Pelat, M; Senard, JM; Verwaerde, P, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.45) | 18.7374 |
| 1990's | 9 (31.03) | 18.2507 |
| 2000's | 18 (62.07) | 29.6817 |
| 2010's | 1 (3.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, X | 1 |
| Zhao, Y | 1 |
| Shao, H | 1 |
| Zheng, X | 1 |
| Hermida, T | 1 |
| Franco, K | 1 |
| Hadi, F | 1 |
| Douyon, K | 1 |
| Atmaca, M | 2 |
| Kuloglu, M | 2 |
| Tezcan, E | 2 |
| Ustundag, B | 2 |
| Pae, CU | 1 |
| Kim, JJ | 1 |
| Lee, KU | 1 |
| Lee, CU | 1 |
| Bahk, WM | 1 |
| Lee, SJ | 1 |
| Lee, C | 1 |
| Paik, IH | 1 |
| Tavakoli, SA | 1 |
| Arguisola, MS | 1 |
| Littrell, KH | 1 |
| Hilligoss, NM | 1 |
| Kirshner, CD | 1 |
| Petty, RG | 1 |
| Johnson, CG | 1 |
| de la Pierre, M | 1 |
| Aricò, S | 1 |
| Capussotti, L | 1 |
| Dellepiane, M | 1 |
| Marucci, M | 1 |
| Gandini, G | 1 |
| Imarisio, P | 1 |
| Premawardhana, LD | 1 |
| Ismail, IS | 1 |
| Riad-Fahmy, D | 1 |
| Miell, JP | 1 |
| Peters, JR | 2 |
| Scanlon, MF | 2 |
| Maccario, M | 1 |
| Procopio, M | 1 |
| Grottoli, S | 1 |
| Oleandri, SE | 1 |
| Razzore, P | 1 |
| Camanni, F | 1 |
| Ghigo, E | 1 |
| Aquila, R | 1 |
| Emanuel, M | 1 |
| Wirshing, DA | 1 |
| Wirshing, WC | 1 |
| Kysar, L | 1 |
| Berisford, MA | 1 |
| Goldstein, D | 1 |
| Pashdag, J | 1 |
| Mintz, J | 1 |
| Marder, SR | 1 |
| Ganguli, R | 1 |
| Masand, PS | 1 |
| Bryden, KE | 1 |
| Kopala, LC | 2 |
| Pelat, M | 1 |
| Verwaerde, P | 1 |
| Merial, C | 1 |
| Galitzky, J | 1 |
| Berlan, M | 1 |
| Montastruc, JL | 1 |
| Senard, JM | 1 |
| Karagianis, J | 1 |
| Sacchetti, E | 1 |
| Guarneri, L | 1 |
| Bravi, D | 1 |
| Jones, B | 1 |
| Basson, BR | 1 |
| Walker, DJ | 1 |
| Crawford, AM | 1 |
| Kinon, BJ | 1 |
| Allison, DB | 1 |
| Casey, DE | 1 |
| Umbricht, D | 1 |
| Flury, H | 1 |
| Bridler, R | 1 |
| Koren, G | 1 |
| Simpson, MM | 1 |
| Goetz, RR | 1 |
| Devlin, MJ | 1 |
| Goetz, SA | 1 |
| Walsh, BT | 1 |
| Baptista, T | 1 |
| Beaulieu, S | 1 |
| McIntyre, RS | 1 |
| Gothelf, D | 1 |
| Falk, B | 1 |
| Singer, P | 1 |
| Kairi, M | 1 |
| Phillip, M | 1 |
| Zigel, L | 1 |
| Poraz, I | 1 |
| Frishman, S | 1 |
| Constantini, N | 1 |
| Zalsman, G | 1 |
| Weizman, A | 2 |
| Apter, A | 1 |
| Poyurovsky, M | 1 |
| Pashinian, A | 1 |
| Gil-Ad, I | 1 |
| Maayan, R | 1 |
| Schneidman, M | 1 |
| Fuchs, C | 1 |
| Webster, D | 1 |
| Devarajan, S | 1 |
| Gallant, J | 1 |
| Harris, A | 1 |
| Bevan, JS | 1 |
| Ara, J | 1 |
| Page, MD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Placebo-Controlled, Cross-Over Trial of Aripiprazole Added to Obese Olanzapine-Treated Patients With Schizophrenia[NCT00351936] | Phase 4 | 16 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| A Clinical Trial Of Weight Reduction in Schizophrenia[NCT00158366] | 261 participants (Actual) | Interventional | 2004-05-31 | Completed | |||
| Reduction of Body Weight in Olanzapine Treated Schizophrenia Patients by Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids[NCT00211562] | Phase 3 | 20 participants (Actual) | Interventional | 2005-10-31 | Terminated | ||
| The Investigation of the Impact of Atypical Antipsychotics on Brain Functioning in Youths With Conduct Disorder[NCT01867398] | 12 participants (Actual) | Observational | 2013-04-29 | Terminated | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Evaluating change in Body Mass Index (BMI) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | kg/m^2 (Mean) |
|---|---|
| Aripiprazole | -0.4 |
| Placebo | 0.3 |
Evaluating change in fasting total cholesterol between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -3 |
| Placebo | 9 |
Evaluating change in high-density lipoprotein cholesterol (HDL-C) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | 0.4 |
| Placebo | 0.6 |
Evaluating change in low-density lipoprotein (LDL) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -0.2 |
| Placebo | 3.1 |
Evaluating change in triglyceride levels between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -51.7 |
| Placebo | 47.6 |
Evaluating change in waist-hip ratio (WHR) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | cm (Mean) |
|---|---|
| Aripiprazole | 0.0 |
| Placebo | 0.0 |
Evaluating change in weight (lbs) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | lbs (Mean) |
|---|---|
| Aripiprazole | -2.9 |
| Placebo | 2.1 |
2 reviews available for pirenzepine and Obesity
| Article | Year |
|---|---|
Weight change and atypical antipsychotic treatment in patients with schizophrenia.
Topics: Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Dose-Response Relationship, Drug; Follow-Up | 2001 |
Antipsychotic-induced weight gain: a review of the literature.
Topics: Adult; Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Body Mass Index; Female; Humans; Mal | 2001 |
8 trials available for pirenzepine and Obesity
| Article | Year |
|---|---|
Effect of nizatidine on olanzapine-associated weight gain in schizophrenic patients in Korea: a pilot study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Histamine H2 Antagonists; Humans; Male; Nizati | 2003 |
Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Histamine H2 Antagonists; | 2003 |
The effects of an educational intervention on antipsychotic-induced weight gain.
Topics: Adult; Antipsychotic Agents; Attitude to Health; Benzodiazepines; Body Mass Index; Female; Health Kn | 2003 |
Acute cholinergic blockade with low dose pirenzepine reduces the insulin and glucose responses to a mixed meal in obese women with the polycystic ovary syndrome.
Topics: Adult; Androstenedione; Blood Glucose; Carrier Proteins; Dose-Response Relationship, Drug; Eating; F | 1994 |
Novel antipsychotics: comparison of weight gain liabilities.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Haloperidol; Humans; I | 1999 |
Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Eating; Energy Inta | 2002 |
Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Double-Blind Method; Drug Therapy, Co | 2002 |
Cholinergic blockade with pirenzepine induces dose-related reduction in glucose and insulin responses to a mixed meal in normal subjects and non-insulin dependent diabetics.
Topics: Adult; Blood Glucose; Circadian Rhythm; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dose-Respo | 1991 |
19 other studies available for pirenzepine and Obesity
| Article | Year |
|---|---|
Metabolic and endocrinal effects of N-desmethyl-olanzapine in mice with obesity: Implication for olanzapine-associated metabolic changes.
Topics: Animals; Benzodiazepines; Blood Glucose; Body Weight; Dyslipidemias; Energy Metabolism; Fatty Liver; | 2019 |
Weight gain associated with atypical antipsychotics.
Topics: Adolescent; Benzodiazepines; Child; Dopamine Antagonists; Female; Haloperidol; Humans; Male; Obesity | 2002 |
Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Dibenzothiazepines; Female | 2003 |
Diabetic ketoacidosis in a patient treated with olanzapine, valproic acid, and venlafaxine.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepi | 2003 |
[Description of a case of Zollinger-Ellison syndrome].
Topics: Benzodiazepinones; Body Weight; Cimetidine; Diarrhea; Female; Gastrectomy; Gastric Acid; Humans; Mid | 1984 |
In obesity the somatotrope response to either growth hormone-releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose.
Topics: Adult; Arginine; Female; Glucose; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Male; Mu | 1995 |
Weight gain and antipsychotic medications.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Obesity; Olanzapine; Pirenzepine; Risperid | 1999 |
Weight gain associated with antipsychotic drugs.
Topics: Administration, Oral; Antipsychotic Agents; Benzodiazepines; Clozapine; Delayed-Action Preparations; | 1999 |
Relative weight gain among antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Obesity; Olanzapine; Pirenzepine; Risperid | 1999 |
Body mass index increase of 58% associated with olanzapine.
Topics: Adolescent; Benzodiazepines; Body Mass Index; Humans; Male; Obesity; Olanzapine; Pirenzepine; Schizo | 1999 |
Impaired atrial M(2)-cholinoceptor function in obesity-related hypertension.
Topics: Adenylyl Cyclases; Animals; Blood Pressure; Body Weight; Dogs; Dose-Response Relationship, Drug; Hea | 1999 |
Olanzapine and weight gain.
Topics: Adult; Benzodiazepines; Female; Humans; Obesity; Olanzapine; Pirenzepine; Psychotic Disorders; Selec | 2000 |
H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients.
Topics: Adult; Benzodiazepines; Brief Psychiatric Rating Scale; Histamine H2 Antagonists; Humans; Male; Niza | 2000 |
Cognitive behavior therapy for weight gain.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Cognitive Behavioral Ther | 2001 |
Maternal obesity and risk of neural tube defects.
Topics: Antipsychotic Agents; Benzodiazepines; Female; Folic Acid; Humans; Infant, Newborn; Neural Tube Defe | 2001 |
Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Drug Administration Schedu | 2001 |
Body weight gain, insulin, and leptin in olanzapine-treated patients.
Topics: Antipsychotic Agents; Benzodiazepines; Body Weight; Female; Humans; Insulin; Leptin; Male; Metabolic | 2001 |
Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited.
Topics: Anticonvulsants; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Female; Fructose; Humans; La | 2002 |
Extreme weight gain in a youth with schizophrenia: risk/benefit considerations.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Follow-Up Stud | 2002 |